The Filing Desk

Nurix Therapeutics vs Zymeworks

Nurix Therapeutics NRIX · Zymeworks ZYME · Pharmaceuticals

Zymeworks reported revenue of $106 million in fiscal 2025, 1.3 times Nurix Therapeutics' $84 million in fiscal 2025. Nurix Therapeutics' revenue grew 54.0% in its latest year, and Zymeworks' grew 38.9%. Nurix Therapeutics had an operating margin of -340.2%, against -87.3% at Zymeworks. Free cash flow was −$263 million at Nurix Therapeutics and −$35 million at Zymeworks. Their fiscal years end in different months (November 30 and December 31), so the periods don't line up exactly.

Side by side

Nurix TherapeuticsZymeworks
Latest fiscal yearFY2025, Nov 30, 2025FY2025, Dec 31, 2025
Revenue$84M$106M
Revenue growth54.0%38.9%
Revenue growth a year, last 5 years36.4%22.1%
Gross margin——
Operating margin−340.2%−87.3%
Net margin−314.9%−76.6%
Free cash flow−$263M−$35M
Free cash flow margin−313.7%−32.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$42M
Change in diluted share count29.1%−0.6%
Last close$15.48$26.24
P/E at the last close6.7×50.5×
Insider trades, last 12 monthssold $4.2 millionsold $4.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Nurix TherapeuticsZymeworks
Operating margin
Percent of revenue
Nurix TherapeuticsZymeworks
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nurix TherapeuticsZymeworks

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nurix Therapeutics and Zymeworks pages.